Argenx Se logo

Argenx Se(NASDAQ) ARGX

Market Cap$54.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+3,681%
5 Year+204%
1 Year+7%
1 Month-10%
Premium Feature
Moneyball Superscore
89/100
$886.55
+1.93%
+16.83Today
After hours$889.30+$2.75 (+0.31%)
Argenx Se last closing stock price
MetricPriceDate
Last closeUSD 890.052026-10-21
Argenx Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.77%USD 818.302026-10-14
1 month-9.93%USD 988.202026-09-21
3 month-3.74%USD 924.602026-07-23
Year to date+5.84%USD 840.952025-12-31
1 year+6.62%USD 834.752025-10-21
3 year+87.35%USD 475.072023-10-20
5 year+203.61%USD 293.162021-10-22
Since inception+3,681.39%USD 23.002017-05-18

Argenx Se Financials at a Glance

Market Cap

$54.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.54B

Net Income (TTM)

$2.22B

EPS (TTM)

$26.24

P/E Ratio

31.36

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$886.55

Volume

656,687.092

Open

$875.27

Previous Close

$890.05

Daily Range

$873.23 - $892.85

52-Week Range

$661.85 - $1,072.75

Estimated Earnings Date

Mar 4, 2027

ARGX News

Stock chart rocket

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

Keith SpeightsOct 5, 2026
excited investor looks at financial charts on computer.

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months

Keith SpeightsSep 26, 2026
Stock chart rocket

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Keith SpeightsSep 20, 2026
A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsSep 11, 2026
Scientists in a lab

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Keith SpeightsSep 2, 2026
Scientists smiling and shaking hands

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Keith SpeightsAug 26, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

How to Invest in iShares Biotechnology ETF (IBB)

Tony DongFeb 25, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in VanEck Biotech ETF (BBH)

Tony DongFeb 25, 2026
Page 1

ARGX: Motley Fool Moneyball Superscore

89

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Argenx Se

argenx SE is a biotechnology company based in Amsterdam, dedicated to developing innovative therapies primarily for autoimmune diseases. Established in 2008, the company operates across key global markets, focusing on addressing a broad range of conditions through its leading investigational therapy, efgartigimod.

Products and Services
  • efgartigimod for various autoimmune diseases
  • Extensive pipeline including ARGX-119 and ARGX-213
  • Proprietary products like VYVGART and VYVGART HYTRULO
Growth Outlook
  • Recent quarterly revenue reached $2.82 billion, showcasing strong market demand
  • Pipeline includes multiple candidates targeting significant unmet medical needs
  • Strategic collaborations enhance research capabilities and market reach
Financial Highlights
  • Net income for Q2 2026 was $838.82 million, reflecting robust profitability
  • Cash and short-term investments totaled $5.18 billion, ensuring liquidity
  • Operating income margin stood at 30%, indicating efficient operations
AI Generated • Oct 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,863

CEO

Tim van Hauwermeiren, EMBA

Website

www.argen-x.com

Headquarters

Amsterdam, NH 1101 EB, NL

ARGX Financials

Key Financial Metrics (TTM)

Gross Margin

89.94%

Operating Margin

28.81%

Net Income Margin

32.87%

Return on Equity

21.66%

Return on Capital

14.24%

Return on Assets

16.99%

Earnings Yield

3.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$54.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.89M

Volume

656.69K

Avg. Volume

334.68K

Financials (TTM)

Gross Profit

$6.75B

Operating Income

$1.92B

EBITDA

$2.27B

Operating Cash Flow

$1.64B

Capital Expenditure

-$10.14M

Free Cash Flow

$1.63B

Cash & ST Invst.

$5.18B

Total Debt

$47.00M

Argenx Se Performance Analysis

Argenx Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 410,970,991-17.2%
20232023-12-31USD 1,228,215,279198.9%
20242024-12-31USD 2,186,362,05978.0%
20252025-12-31USD 4,166,333,71790.6%
Argenx Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3143.0%
Q22025-06-3065.4%
Q42025-12-31238.1%
Q22026-06-30-12.2%
Argenx Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.0663.6%
20232023-12-31USD -5.17-60.4%
20242024-12-31USD 12.76N/A
20252025-12-31USD 19.6353.8%
Argenx Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31233.7%
Q22025-06-30358.3%
Q42025-12-31107.5%
Q22026-06-30-1.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.82B

+602.2%

Gross Profit

$2.54B

+608.9%

Gross Margin

90.08%

N/A

Market Cap

$54.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$29.36M

N/A

Employees

1,863

N/A

Net Income

$838.82M

+1461.8%

EBITDA

$863.85M

+1424.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.18B

+67.1%

Total Debt

$47.00M

+38.4%

Accounts Receivable

$1.94B

+196.1%

Inventory

$371.00M

+13.6%

Long Term Debt

$36.00M

+28.1%

Short Term Debt

$11.00M

+87.9%

Return on Assets

16.99%

N/A

Return on Invested Capital

17.67%

N/A

Free Cash Flow

$748.74M

+696.8%

Operating Cash Flow

$751.74M

+703.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIIBBiogen Inc.
$240.98-0.87%
INCYIncyte Corporation
$113.44-2.72%
TGTXTG Therapeutics, Inc.
$53.20-2.44%
AMGNAmgen Inc.
$438.34-0.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$159.31+7.80%
NFLXNetflix
$65.04-5.31%
NVDANvidia
$221.97+2.54%
TAT&T
$21.91-6.45%

Questions About ARGX

What is the current price of Argenx Se?

Argenx Se is trading at $890.05 per share.

What is the 52-week range for Argenx Se?

Over the past 52 weeks, Argenx Se has traded between $661.85 and $1,072.75.

How much debt does Argenx Se have?

As of the most recent reporting period, Argenx Se reported total debt of $47.16M.

How much cash does Argenx Se have on hand?

Argenx Se reported $3.49B in cash and cash equivalents in its most recent financial results.

What is Argenx Se’s dividend yield?

Argenx Se does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services